Survival analysis of triple negative and her2 positive breast cancer patients: single center report
Küçük Resim Yok
Tarih
2014
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Triple negatif ve insan epidermal büyüme faktör reseptörü 2 (Her2) pozitif meme tümörleri, östrojen ve progesteron reseptörlerinin negatif olması ve HER-2 ekspresyonun olup olmaması ile karakterizedir. Diğer meme kanserleri ile karşılaştırıldığında daha büyük ve daha yüksek dereceli tümörlerdir, erken nüks ve metastaz sıklığı daha fazladır. Bu yazıda yüksek riskli meme kanserlerinin klinik, patolojik ve moleküler özellikleri ve bu özelliklerin nüks ile ilişkisi araştırılacaktır. Yöntem ve Gereçler: Hastanemiz tıbbi onkoloji kliniğinde 2004 ile 2011 yılları arasında takip edilen, adjuvan veya neoadjuvan tedavi almış 109 Triple negatif ve 81 Her2 pozitif meme kanser tanısı olan toplam 190 hasta retrospektif olarak incelenmiştir. Bulgular: Hastaların yaş ortalaması 51 ve 52’dir. Ortanca takip süresi 22 (IQR: 11-30 ay) ve 29 (IQR: 20-39 ay) aydır. Her grupta toplam 4 hasta takip sırasında eksitus olmuştur. 5 yıllık genel sağkalım oranları triple nega- tif grupta %81,1, Her2 pozitif grupta %73,5 olarak belirlenmiştir. Taki- plerde 30 hastada nüks gelişmiştir. Birinci ve ikinci grupta en sık görülen nüksler sırasıyla kemik ve beyindir. Triple negatif hastalar arasında tümör çapı daha büyük olanlarda, Her2 pozitif hastalarda ise tanı anında lenf nodu pozitif olanlarda ve adjuvan radyoterapi almayanlarda nüks riski istatistiksel anlamlı olarak daha fazla bulunmuştur. Sonuç: Kısa izlem süresine rağmen hastalarımızın yaklaşık altıda birinde nüks gözlenmesi, bu yüksek riskli hastalardaki agresif seyri desteklemekte- dir. Dolayısıyla her iki hasta grubunda da, hastalık nüksünü erken dönemde öngörülebilecek risk faktörlerinin saptanması önem taşımaktadır.
Objective: Triple negative and human epidermal growth factor receptor 2 (Her2) positive breast tumors are characterized by the absence of expression of estrogen and progesterone receptors and with either Her2 expression or not. Generally, they are larger tumors with higher grade, higher incidence of recurrence and distant metastasis. This article will investigate clinical, pathological, and molecular features of these high risk breast cancer patients and whether these features are correlated with recurrences or not. Materials and Methods: Breast cancer patients of 109 triple negative and 81 Her2 positive histology followed in the medical oncology department of our hospital between 2004 and 2011 were enrolled in the study. These patients were mostly treated with adjuvant and neoadjuvant chemotherapy. Results: the median age of patients was 51 and 52 years. Median follow-up duration was 22 and 29 months. Four patients in each group died during the follow-up. 5 year survival rates were 81.1% in triple negative group and 73.5% in Her2 positive group. Relapses were seen in 30 patients. Bone and brain were the most common metastatic sites in the first and second groups respectively. Triple negative patients having larger tumor size and Her2 posi- tive patients having positive lymph node or not treated with radiotherapy have a statistically higher chance of relapse during the follow-up. Conclusion: Despite the short median follow-up time, approximately one sixth of our patients had recurrence and this supported the aggressive course of the disease in high risk patients. For this reason, risk factors that help us to predict the early recurrences in both of the groups are very important.
Objective: Triple negative and human epidermal growth factor receptor 2 (Her2) positive breast tumors are characterized by the absence of expression of estrogen and progesterone receptors and with either Her2 expression or not. Generally, they are larger tumors with higher grade, higher incidence of recurrence and distant metastasis. This article will investigate clinical, pathological, and molecular features of these high risk breast cancer patients and whether these features are correlated with recurrences or not. Materials and Methods: Breast cancer patients of 109 triple negative and 81 Her2 positive histology followed in the medical oncology department of our hospital between 2004 and 2011 were enrolled in the study. These patients were mostly treated with adjuvant and neoadjuvant chemotherapy. Results: the median age of patients was 51 and 52 years. Median follow-up duration was 22 and 29 months. Four patients in each group died during the follow-up. 5 year survival rates were 81.1% in triple negative group and 73.5% in Her2 positive group. Relapses were seen in 30 patients. Bone and brain were the most common metastatic sites in the first and second groups respectively. Triple negative patients having larger tumor size and Her2 posi- tive patients having positive lymph node or not treated with radiotherapy have a statistically higher chance of relapse during the follow-up. Conclusion: Despite the short median follow-up time, approximately one sixth of our patients had recurrence and this supported the aggressive course of the disease in high risk patients. For this reason, risk factors that help us to predict the early recurrences in both of the groups are very important.
Açıklama
Anahtar Kelimeler
Cerrahi
Kaynak
Meme Sağlığı Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
10
Sayı
1
